FONDATION-IPSEN
26.11.2015 15:01:22 CET | Business Wire | Press release
The 20th annual Longevity Prize of the Fondation IPSEN has been awarded to Steven N. Austad (University of Alabama at Birmingham, USA ), in recognition of his outstanding leadership in the domain of the comparative biology of aging (especially the study of species resisting to aging), by an international jury led by Thomas Kirkwood (Newcastle University, Newcastle, UK ). He received the €20,000 prize on November 21st , 2015 at the Gerontology Society of America (GSA) in Orlando, USA where he presented an outstanding lecture.
“Evolution is smarter than you are.” That quote from biochemist Leslie Orgel forms the basis for looking to nature for creative ways to slow the damaging processes of aging. Ironically, the laboratory animals scientists generally use to try to understand aging processes – and learn how to retard them – are demonstrably unsuccessful at combating these degenerative processes. It doesn’t take long to determine whether the researchers have succeeded in lengthening their health- and lifespan. On the other hand, methods for making an animal that normally lives 2 years survive to age 4, may not be relevant for an animal – humans – that already lives 80 years or more. A complementary approach is to scour nature for animals that nature has already given the tools to combat aging successfully and to try to discover what those tools are and how they work. Animals that are more successful than humans at resisting aging processes are abundant on earth. The research of Steven N. Austad has employed a number of such species over the years.
Dr. Austad is Distinguished Professor and Chair of the Department of Biology at the University of Alabama at Birmingham and also Scientific Director of the American Federation for Aging Research. After receiving his PhD degree from Purdue University, he accepted his first faculty position as Assistant Professor at Harvard University in 1986. He subsequently moved to the University of Idaho where he became full professor in 1997. In 2004, he joined the Barshop Institute for Longevity & Aging Studies at the University of Texas Health Science Center San Antonio in San Antonio, Texas before moving to his current position in 2014. His research encompasses many aspects of the biology of aging from the molecular to the population level. His research specialty is the identification and study of nontraditional species – particularly exceptionally long-lived species – for insight into processes of slow aging. Dr. Austad’s research has won multiple previous awards, including the Geron Corporation-Samuel Goldstein Distinguished Publication Award, the Nathan A. Shock Award, the Robert W. Kleemeier Award, the Purdue Outstanding Alumnus Award, and the Irving S. Wright Award of Distinction.
Previous laureates of the Longevity Prize
Founded in 1996,
the Longevity Prize of the Fondation IPSEN has been awarded to renowned
specialists: Caleb E. Finch (Los Angeles, 1996)
, Vaino Kannisto (Lisboa,
1997),
Roy L. Walford (Los Angeles, 1998),
John Morley (St
Louis,1999),
Paul & Margret Baltes (Berlin, 2000),
Justin
Congdon (Aiken, 2001),
George Martin (Seattle, 2002),
James
Vaupel (Rostock, 2003),
Linda Partridge (London, 2004),
Sir
Michael Marmot (London, 2005),
Cynthia Kenyon (San Francisco,
2006),
David Barker (Southampton, 2007),
Gerald McLearn
(University Park, 2008
), Jacques Vallin (Paris, 2009),
Judith
Campisi (Novato, 2010), Tom Kirkwood (Newcastle, 2011),
Linda
Fried (New York, 2012),
Gary Ruvkun (Boston, 2013),
Luigi
Ferrucci (Baltimore, 2014).
The jury members of the Longevity Prize
Thomas Kirkwood (Newcastle
University, Newcastle, UK
), President
Judith Campisi (Buck
Institute for Research on Ageing, Novato, USA
), Eileen Crimmins (University
of Southern California, Los Angeles, USA
), Caleb Finch (University
of Southern California, Los Angeles, USA
), Bernard Jeune (Odense
Universitet, Odense, Denmark
), George Martin (University of
Washington, Seattle, USA
), Jean-Marie Robine (INSERM, Démographie
et Santé, Montpellier, France
), Bruno Vellas (Hôpital Purpan,
Toulouse, France
) and a Fondation IPSEN representative.
About the Fondation IPSEN
Established in 1983 under the
aegis of the Fondation de France, the mission of the Fondation IPSEN is
to contribute to the development and dissemination of scientific
knowledge. The long-standing action of the Fondation IPSEN aims at
fostering the interaction between researchers and clinical
practitioners, which is essential due to the extreme specialization of
these professions. The ambition of the Fondation IPSEN is to initiate a
reflection about the major scientific issues of the forthcoming years.
It has developed an important international network of scientific
experts who meet regularly at meetings known as Colloques Médecine et
Recherche
, dedicated to six main themes: Alzheimer's disease,
neurosciences, longevity, endocrinology, the vascular system and cancer
science. Moreover the Fondation IPSEN has started since 2007 several
meetings in partnership with the Salk Institute, the Karolinska
Institutet, the Massachusetts General Hospital, the Days of Molecular
Medicine Global Foundation as well as with the science journals Nature
,
Cell
and Science
. The Fondation IPSEN produced several
hundred publications; more than 250 scientists and biomedical
researchers have been awarded prizes and research grants.
www.fondation-ipsen.org
View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005262/en/
Contact:
Image Sept
Isabelle de Segonzac, Tel: +33 (0)1 53 70 74 70
Email:
isegonzac@image7.fr
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xylem Releases 2025 Sustainability Report12.5.2026 13:00:00 CEST | Press release
Highlights Measurable Progress on Global Water Challenges As global water challenges intensify, efficient and resilient water management is more critical than ever. Xylem (NYSE: XYL), a leader in global water solutions, has released its 2025 Sustainability Report, demonstrating how customer-driven innovation is transforming sustainability commitments into measurable performance outcomes for communities and the environment. Performance Highlights20 million people reached with access to clean water, sanitation, and hygiene since 2019 15% decrease in injury rate to 0.44 81% employee volunteer participation in 2025, up from 76% in 2023 16% reduction in Scope 1 and 2 (market-based) greenhouse gas emissions since 2023, progressing toward a 42% reduction target by 2030 15% improvement in water efficiency since 2023, progressing toward a 30% reduction goal by 2030 Xylem is globally recognized for sustainability, earning a place on the CDP Climate Change A List, recognition as one of TIME’s 10
GenNx360 Capital Partners Completes Sale of Precision Aviation Group to VSE Corporation for Approximately $2.025 Billion in Cash and Equity.12.5.2026 13:00:00 CEST | Press release
GenNx360 Capital Partners (“GenNx360”), a New York-based private equity firm, has announced the sale of its portfolio company, Precision Aviation Group, Inc. (“PAG” or the “Company”), to VSE Corporation (“VSE”) for a total upfront consideration of approximately $2.025 billion in cash and equity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512000455/en/ Founded in 1996 and headquartered in Atlanta, Georgia, PAG is a best-in-class global provider of aviation maintenance, repair and overhaul (“MRO”) services, distribution and supply chain solutions serving commercial, business and general aviation, rotorcraft and defense end markets. PAG currently operates 29 locations worldwide, employs more than 1,000 people, serves over 10,000 customers globally and completes more than 175,000 repairs annually. The acquisition increases VSE revenue by approximately 50% on a pro forma 2025 basis and is expected to be immediately accreti
Glooko and mylife Diabetes Care Expand Diabetes Data Management Partnership12.5.2026 13:00:00 CEST | Press release
Latest agreement supports connected diabetes data management for people using mylife Loop powered by CamAPS FX, as well as their healthcare teams Glooko, Inc. and mylife Diabetes Care today announced an agreement to further expand their partnership, under which Glooko will serve as mylife Diabetes Care’s primary data management platform for mylife products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512745029/en/ This next step builds on the strong, well-established collaboration between the two companies, ensuring continuity in the way healthcare professionals and patients access data from mylife products, including mylife Loop, an automated insulin delivery (AID) solution powered by mylife CamAPS FX from CamDiab. It also strengthens the shared commitment of both companies to supporting day-to-day clinical practice and improving outcomes. “Diabetes care is increasingly connected, and data management is one of the mos
Telekom Srbija Raises €1.95 Billion Through Landmark Eurobond Transaction, Attracting Record Demand from Global Investors12.5.2026 12:09:00 CEST | Press release
The largest corporate bond issuance from the region attracted nearly USD 14 billion in demand from around 300 global institutional investors, marking a milestone moment for Southeast European capital markets. Telekom Srbija has successfully completed its second international corporate bond issuance, raising approximately €1.95 billion through a multi-tranche offering of senior unsecured notes denominated in U.S. dollars and euros. The transaction generated exceptional investor interest, attracting total demand of USD 13.87 billion from approximately 300 leading international institutional investors, making it the largest corporate bond issuance ever executed in the Southeast / Central and Eastern Europe region, as well as one of the most heavily oversubscribed corporate transactions across emerging markets globally during 2025 and 2026. The issuance attracted participation from many of the world’s most prominent pension funds, insurance companies, sovereign-affiliated investors, and gl
Venture Global Announces LNG Purchase Agreements with TotalEnergies and Vitol12.5.2026 12:00:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) announced the execution of two binding agreements with TotalEnergies and Vitol for the purchase of additional U.S. liquefied natural gas (LNG) from Venture Global. Venture Global announced a new, binding agreement with TotalEnergies for the purchase of approximately 0.85 MTPA of LNG from Venture Global for approximately five years commencing in 2026. Separately, Venture Global and Vitol agreed to increase their existing five-year binding LNG agreement to 1.7 MTPA, up from 1.5 MTPA previously agreed and announced in March 2026. Both agreements will be supplied from Venture Global’s portfolio. “Venture Global is proud to deepen our partnerships with premier global energy companies like Vitol and TotalEnergies,” said Venture Global CEO Mike Sabel. “These agreements reflect the continued confidence and trust in our ability to deliver reliable, low-cost U.S. LNG to global markets quickly and at scale as demand for energy security continues to grow. By
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
